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Abstract One the most important discoveries of the
post-genomic era is that a large fraction of the genome
transcribes a heterogeneous population of noncoding
RNAs (ncRNA). ncRNAs shorter than 200 nucleotides
are usually identified as short/small ncRNAs—examples
include PIWI-interacting RNAs, small interfering
RNAs, and microRNAs (miRNAs)—whereas those longer
than 200 nucleotides are classified as long ncRNAs
(lncRNAs). These molecules are emerging as important reg-
ulators of cellular process, such as development, differentia-
tion, and metabolism. Not surprisingly, ncRNAs are involved
also in human diseases, such as cancer and metabolic and
neuronal disorders. Although the role of miRNAs is being
largely investigated in cardiovascular biology, little is known
about other classes of ncRNA in this field. However, recent
reports have started to reveal the importance of lncRNA in
heart development and suggest also an involvement in heart
failure. Here, we will discuss these reports and the therapeutic
potential of lncRNA for heart failure.
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siRNA Small interfering RNA
eRNA Enhancer RNA
MALAT1 Metastasis-associated lung adenocarcinoma
transcript 1
NEAT2 Nuclear-enriched noncoding transcript 2
PRC1 Polycomb repressive complex 1
PRC2 Polycomb repressive complex 2
Bvht Braveheart
MIAT Myocardial infarction-associated transcript
Introduction
Heart failure (HF) is the ultimate outcome of many
cardiovascular pathologies and a leading cause of mor-
bidity and mortality [1]. It is underlain by gene expres-
sion reprogramming, wherein certain fetal genes are
upregulated while adult genes become downregulated
HF [2, 3]. This reprogramming causes cardiac hypertro-
phy, a pathological event that is ultimately responsible
for a deterioration in heart function. Mechanisms similar
to those that govern gene expression in heart develop-
ment are at the basis of those that occur in HF [4]. The
study of the mechanisms that control cardiac gene ex-
pression in HF and heart development provides informa-
tion conducive to the better understanding of HF patho-
genesis, and could lead to new diagnostic and therapeutic
tools [5].
Over the last few years, one of the greatest surprises
of high-throughput analysis of the transcriptome has
been the discovery of noncoding RNAs (ncRNAs):
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these are a variety of RNAs that are not translated into
a protein, but rather influence gene expression through
various mechanisms—such as RNA interference—at the
level of transcription or translation. Based on size, ncRNAs
can be subdivided into two groups: (1) small ncRNAs
(<200 nt), which include microRNA (miRNA), PIWI-
interacting RNA (piRNA), and endogenous small interfering
RNA (siRNA), and (2) long ncRNAs (lncRNAs), which have
a length between 0.2 and 2 kb and, thus, a coding potential of
less than 100 amino acids [6–9].
So far, a large range of functions have been attributed to
ncRNA, such as cell proliferation, apoptosis, and cell inva-
sion and imprinting, indicating that these molecules may
represent a major regulatory component of the eukaryotic
genome. Not surprisingly, ncRNAs are emerging as impor-
tant players in several human pathologies, including cardio-
vascular diseases [6–9]. Indeed, miRNAs play a key role in
driving the gene expression changes of HF, atherosclerosis,
and cardiac ischemic/reperfusion injury [10]. However, we
are just beginning to understand the biology of piRNA,
siRNA, and lncRNA in the cardiovascular system. Here,
we will give an overview of recent discoveries that
support an important role of lncRNA in heart develop-
ment and heart failure.
Biological Roles of lncRNAs
lncRNAs are currently defined as transcripts greater than
200 nt without known protein-coding function [11]. Though
thousands of lncRNAs have been identified across eukary-
otes, many are species specific and appear less conserved
than protein-coding genes [12, 13].
Based on genomic distribution, lncRNAs can be classified
into one ormore of the following five categories: (1) sense, when
overlapping one or more exons of another transcript on the same
strand; (2) antisense, when overlapping one or more exons of
another transcript on the opposite strand; (3) bidirectional, when
expression of the lncRNA and a neighboring coding transcript on
the opposite strand is initiated in close genomic proximity, (4)
intronic, when derived from an intron of a second transcript;
and/or (5) intergenic, when it lies as an independent unit within
the genomic interval between two genes (Fig. 1).
Although only a very small percentage of identified lncRNAs
have been explored experimentally, they are known to be impli-
cated in many biological processes, such as X chromosome
inactivation and genomic imprinting, nuclear compartmentaliza-
tion and architecture, cell fate specification, RNA splicing, trans-
lational control, and chromatin modification [14]. Below we
summarize the main recent findings on these functions:
Fig. 1 Biogenesis of long noncoding RNAs. Schematic diagram depicting
the network of long noncoding transcript (black box) associated with a
representative gene (gray box). a Sense lncRNA: the lncRNA sequence
overlaps with the sense strand of a protein-coding gene; b intronic lncRNA:
the lncRNA sequence derives exclusively from within an intron of another
transcript. This may be either a true independent transcript or a product of
pre-mRNA processing; c bidirectional lncRNA: the lncRNA sequence is
located on the opposite strand to that of a protein-coding gene whose
transcription is initiated <1,000 base pairs away; d, e antisense lncRNA:
the lncRNA sequence overlaps with the antisense strand of a protein-
coding gene; f intergenic lncRNA: the lncRNA sequence is not located
near any other protein-coding loci
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X chromosome Inactivation and Genomic Imprinting One of
the best-studied lncRNAs to date is Xist. Discovered in 1991,
it is widely accepted to be required for the silencing of hun-
dreds of genes on the inactive X chromosome in female
somatic cells by favoring the formation of a chromatin struc-
ture with an epigenetic profile linked to transcription repres-
sion, a process known as X chromosome inactivation (XCI)
[15]. However, despite having been studied extensively, the
exact mechanism of Xist-mediated XCI is yet to be fully
elucidated [14].
lncRNAs are also implicated in genomic imprinting, a
process that inactivates either the maternally or the paternally
inherited allele. Imprinted genes play crucial roles in mam-
malian development, and so their expression must be highly
regulated. Intriguingly, many imprinted gene loci express, in
addition to mRNAs, a significant number of lncRNAs (e.g.,
Air, H19, and Kcnq1ot1) that appear to play major roles in
regulating the expression of neighboring imprinted protein-
coding genes in cis [16].
Nuclear Compartmentalization and Architecture The con-
tribution of lncRNAs in the building of a cell’s archi-
tecture is well known. A clear example comes from
paraspeckles—ribonucleoprotein bodies found in the
interchromatin space of mammalian cell nuclei—which
play a central role in regulating gene expression during
cell differentiation. These structures control many aspects of
transcription and RNA processing, such as transcription initi-
ation, coactivation and corepression, RNA splicing, and tran-
scription termination, through retention of RNA in the nucleus
[17]. Given the large numbers of long noncoding transcripts
currently being discovered through whole-transcriptome anal-
ysis, paraspeckles may be a paradigm for a class of sub-
nuclear bodies formed around lncRNA.
Cell Fate Specification It is well accepted that many
lncRNAs provide an additional layer of regulation in the
specification of cellular identities through the regulation of
gene expression at transcriptional and translational levels
[18]. Recently, the muscle-specific lncRNA linc-MD1 was
identified as a regulator of muscle cell differentiation, by
acting as a competing endogenous RNA in mouse and hu-
man myoblasts. Downregulation and over-expression of
linc-MD1 correlate with retardation and anticipation of the
muscle differentiation program, respectively [19].
RNA Splicing and Translational Control Alternative splicing
of pre-mRNAs increases the diversity of the proteome by
generating different protein products having non-overlapping
functions from a single mRNA.MALAT1 (metastasis-associat-
ed lung adenocarcinoma transcript 1) was originally identified
as a gene that was specifically upregulated in metastatic non-
small cell lung cancer cells, but has subsequently been re-
characterized as an lncRNA that accumulates in the nucleus
and is now referred to as NEAT2 (nuclear-enriched noncoding
transcript 2) [20]. This lncRNA regulates alternative splicing
through its interaction with serine-/arginine-rich (SR) nuclear
phosphoproteins involved in the splicing machinery [21].
Chromatin Modification lncRNAs have been proposed to
regulate transcription by recruiting chromatin-remodeling
complexes, which in turn mediate epigenetic changes. For
example, Kcnq1ot1, Airn, Xist, and HOTAIR are four
lncRNAs that act to promote the formation of repressive
chromatin structure across large genomic regions and even
entire chromosomes. This is achieved through recruitment of
epigenetic enzymes, such as polycomb repressive complex 1
(PRC1) and polycomb repressive complex 2 (PRC2), which
mediate mono-ubiquitinylation of lysine 119 on histone 2A
and trimethylation of lysine 27 on histone H3, respectively
[22, 23].
Another class of ncRNA that has received much emphasis
is found expressed at enhancer regions: this type of RNA has
been named enhancer RNA (eRNA). The size of eRNA
ranges from 0.1 to 9 kb, comprising an average of 800 nt.
Most promote transcription of neighboring genes. An exam-
ple is ncRNA-a7, which acts in cis to induce transcriptional
activation of the nearby gene Snai1 [24].
There are probably many other functions of lncRNAs
awaiting discovery. For example, the lncRNA NRON has
been shown to regulate nuclear trafficking of the transcrip-
tion factor nuclear factor of activated T cells, and the obser-
vation that many lncRNAs are located in the cytoplasm
suggests that they might have undiscovered roles in cell
biology [25].
Molecular Mechanisms of lncRNAs
The precise mechanism of how lncRNAs function still re-
mains largely unknown and is the subject of intense investi-
gation. Wang and Chang have proposed to classify the mo-
lecular mechanisms of lncRNAs into four main categories
(Fig. 2) [8]:
Signal lncRNAs These lncRNAs can serve as molecular
signals because transcription of individual lncRNAs oc-
curs at very specific times and places in order to inter-
pret cellular context or to respond to diverse stimuli.
For instance, Air and Kcnq1ot1 mediate the transcrip-
tional silencing of multiple genes by interacting with
chromatin and recruiting the chromatin-modifying ma-
chinery [8, 26].
Decoy lncRNAs The molecular decoy type of activity takes
place when specific lncRNAs are transcribed and then bind
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to and titrate away protein factors. Decoy lncRNAs can
“sponge” protein factors such as transcription factors and
chromatin modifiers. This leads to broad changes in the cell’s
transcriptome. One of the most abundant nuclear lncRNAs in
mammalian cells is NEAT2, which is localized in nuclear
speckles. NEAT2 binds to and sequesters several SR splicing
factors to nuclear speckles. Depletion of NEAT2 alters
splicing-factor localization and activity, leading to an altered
pattern of alternative splicing for a set of pre-mRNAs [27].
Guide lncRNAs These can act as molecular chaperons by
localizing particular ribonucleoprotein complexes to specific
chromatin targets. This activity can cause changes in the
gene expression of neighboring (cis) or distantly located
(trans) genes that cannot be easily predicted by just the
lncRNA sequence itself. Examples are HOTAIR and
HOTTIP, both transcribed within the human HOX clusters.
HOTTIP may organize chromatin domains to coordinate
long-range gene activation by serving as key intermediates
that transmit information from higher order chromosomal
looping into chromatin modifications. In contrast, lncRNAs
such asHOTAIR are able to alter and regulate epigenetic states
in cells through their targeting of chromatin-modifying com-
plex occupancy/localization/enzymatic activity in trans [28].
Scaffold lncRNAs Some lncRNAs possess multiple domains
that bind distinct proteins. The complexes formed perform
functions such as transcriptional activation or repression.
Thus, the lncRNA serves as an adaptor to form the functional
protein complexes. The telomerase RNA TERC (TERRA),
which is part of telomeric heterochromatin in addition to
being present in the nucleoplasm, is a classic example of an
RNA scaffold and is essential for telomerase function [29].
Are lncRNAs Important Players of Heart Development?
Over recent years, next-generation sequencing technologies
have enabled the study of transcriptomes in various cell
types at different developmental stages. These studies have
revealed that the expression of many lncRNAs is regulated
during development and that their role ranges from the
control of pluripotency to lineage specification [29–31].
For instance, XCI is tightly correlated with both early em-
bryonic development and pluripotency in embryonic stem
cells and induced pluripotent stem cells [32]. Knockdown of
dozens of lncRNAs causes either exit from the pluripotent
state or upregulation of lineage commitment programs, dem-
onstrating that lncRNAs play key roles in the circuitry con-
trolling the embryonic stem cell state [33]. The role of
lncRNA in heart development is only starting to emerge.
Indeed, two recent reports demonstrated that two lncRNAs,
Fendrr and Braveheart (Bvht), are involved in defining the
gene transcription program underlying the development of
Fig. 2 Molecular mechanism of long noncoding RNAs. Schematic
diagram illustrating the four molecular mechanisms of lncRNAs. a
Signaling lncRNA: the combination of lncRNAs and transcription
factors may affect gene regulation in space and time; b decoy lncRNA:
lncRNAs can displace transcription factors and other complexes away
from the chromatin, leading to the silencing of a nearby gene; c guide
lncRNA: lncRNAs may guide chromatin-modifying enzymes to their
site of action, either in cis or in trans; d scaffold lncRNA: lncRNAs can
induce the assembly of multiple proteins, forming ribonucleoprotein
complexes affecting histone modifications. TF transcription factor, CME
chromatin-modifying enzymes, RbNC ribonucleoprotein complexes
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lateral mesoderm in heart and the differentiation of
cardiomyocytes, respectively [34, 35].
Fendrr is specifically expressed in nascent lateral plate
mesoderm and is required for the correct development of this
tissue in heart and the body wall. Indeed, Fendrr-deficient
mice die around E13.75 due to abnormal functioning of the
heart. The heart of these mice presents with a thin ventricular
wall, caused by cardiac hypoplasia linked to an altered prolif-
eration of cardiac myocytes at later stages of heart develop-
ment. Fendrr regulates the expression of important transcrip-
tion factors, such GATA-6, NKX2-5, FOXF1, TBX3, IRX3,
and PITX2, by controlling the epigenetic profile of the pro-
moters of these genes. In fact, Fendrr can bind either to PRC2
or to the Trithorax group/MLL protein complex (TrxG/MLL),
which induces trimethylation of lysine 27—an H3 histone
marker associated with transcription activation—and trime-
thylation of lysine 4 on histone H3—a marker associated with
transcription activation—respectively [34] (Fig. 3). This
lncRNA–protein interaction targets the complexes to the pro-
moters of specific genes (Table 1).
The lncRNA Braveheart (Bvht) is required for cardio-
myocyte differentiation in vitro and for maintaining the
cardiac phenotype in neonatal cardiomyocytes. Bvht is re-
quired for expression of core gene regulatory networks in-
volved in defining cardiovascular cell fate and acts upstream
of mesoderm posterior (MesP1), a master gene of cardiovas-
cular lineage commitment. In a similar way to Fendrr, Bvht
regulates cardiomyocyte differentiation by modulating the
epigenetic profile of cells through interaction with SUZ12, a
component of PRC2 [35].
lncRNA: a Possible Player in Heart Failure
If we are only at the beginning of understanding the role of
lncRNA in heart development, we are even further away
from comprehending the function of these molecules in
cardiovascular disease. However, recent studies have started
to investigate their role in this area. A genome-wide associ-
ation study (GWAS) found six single-nucleotide polymor-
phisms (SNP) in the lncRNA MIAT (myocardial infarction-
associated transcript) associated with myocardial infarction;
one SNP (A11741G) caused a 1.3-fold increase in MIAT
transcription in vitro [36].
Another study revealed 15 lncRNAs modulated in the
heart of mice subjected to aortic constriction—a procedure
that, through the creation of pressure overload, induces first
compensated hypertrophy and then HF [37].
Moreover, transcription in the heart of Kcnq1—a gene
encoding a potassium channel—depends on the expression
of the lncRNA Kcnq1ot1. This is an unspliced, ∼60 kb
lncRNA whose transcription starts at intron 10 of Kcnq1
and in the opposite direction to that of the host gene. Mice
that express a truncated Kcnq1ot1 have an increased expres-
sion of Kcnq1. Because correct potassium channel activity is
required for normal cardiac functioning, any alteration of the
Kcnq1ot1-mediated control of Kcnq1 could be responsible
for abnormal heart function [38].
The involvement of lncRNA in HF is also suggested by
the role of ANRIL (antisense noncoding RNA in the INK4
locus) in coronary heart disease [39]. This lncRNA is an
antisense noncoding RNA transcribed with the INK4b–
ARF–INK4a gene cluster, which encodes oncosuppressor
proteins p15INK4b, p14 ARF, and p16INK4a. GWAS revealed
that many SNPs mapped to this genomic locus and, in
particular, to the gene encoding ANRIL and were associated
with increased susceptibility to coronary artery disease and
several other diseases, including cancer. ANRIL regulates the
expression of the INK4b–ARF–INK4a gene cluster through
recruitment of both PRC1 and PRC2, promoting the forma-
tion of a repressive chromatin structure [40]. In the light of
these findings, it was proposed that loss-of-function muta-
tions in this lncRNA lead to altered expression of p15INK4b,
p14 ARF, and p16INK4a, influencing thus the susceptibility to
coronary heart disease and cancer.
lncRNA: a Possible Therapeutic Target for Heart
Failure?
A therapeutic strategy for HF is to cure the sick heart cells by
interfering with the gene expression program that underlies
Fig. 3 Schematic representation of the mechanism of action of Fendrr
in heart development. This lncRNA can either induce gene transcription
repression or promote gene transcription through the recruitment of
PRC2 (a) or TrxG/MLL (b), respectively, on promoters of gene targets
during heart development
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HF. To this end, novel therapeutic opportunities might arise
from RNA-based strategies that consist in the use of synthet-
ic RNAs capable of programming biological function. The
potential of this strategy for HF is supported by the discovery
of the role of miRNAs in triggering the gene expression
program of HF and by the possibility of manipulating
ncRNAs in vivo. Indeed, anti-miRNAs and antisense oligo-
nucleotides are being employed to inhibit the expression of
specific miRNAs in vitro and in vivo for investigative and
clinical purposes [41, 42]. The use of the same strategies for
lncRNA could open new therapeutic avenues for HF, over-
coming problems linked to the use of miRNA-based
molecules, such as low specificity and poor pharmacokinetics.
Indeed, future studies on the role of lncRNA in HF and
heart development will improve our understanding of the
ncRNA network involved in regulating gene expression
changes underlying HF and, thus, allow the development
of specific therapeutic strategies based on the interfer-
ence not only of miRNAs but also of lncRNA important
for HF. These studies will greatly benefit from the com-
bination of next-generation sequencing technologies ap-
plied to RNA (RNA-seq) with bioinformatics tools de-
veloped to identify lncRNAs that are differentially
expressed in different biological conditions and for the
Table 1 Long noncoding RNAs
with a possible association with
heart diseases
lncRNA Cardiac function Heart disease
Fendrr Required for the development of
lateral plate mesoderm regulating
the expression of GATA-6, NKX2-5,
FOXF1, TBX3, IRX3, and PITX2 genes
None described [34]
Bvht Required for cardiomyocyte differentiation None described [35]
MIAT Unknown Myocardial infarction [36]
Kcnq1ot1 Regulates the expression of the potassium
channel KCNQ1
None described [38]
ANRIL Represses the expression of oncosuppressor
genes INK4b, ARF, and INK4a
Coronary heart disease [39]
Table 2 A list of bioinformatics
tools for lncRNA discovery and
investigation
Tool Description Link










and tests for differential expression
and regulation in RNA-Seq samples
cufflinks.cbcb.umd.edu/ [44]




RIsearch RIsearch is a program for fast
RNA–RNA interaction search
rth.dk/resources/research/ [46]
RNAz RNAz is a program for
predicting structurally conserved




RNAclust RNAclust is a perl script summarizing all
the single steps required for clustering
of structured RNA motifs
bioinf.uni-leipzig.de/∼kristin/
Software/RNAclust/
ORF Finder The ORF Finder is a tool which finds
all open reading frames of a selectable
minimum size in a user's sequence
bioinformatics.org/sms2/orf_
find.html [48]
Pfam The Pfam database is a large collection
of protein families, each represented by
multiple sequence alignments and hidden
Markov models
pfam.sanger.ac.uk/ [49]
Rfam The Rfam database is a collection of RNA
families, each represented by multiple
sequence alignments, consensus secondary
structures, and covariance models
rfam.sanger.ac.uk/ [50]
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prediction of their mechanism of action. Table 2 lists
some bioinformatics tools used today to study lncRNAs.
Conclusion
Considering the growing interest in synthetic ncRNA for
therapeutic application and the diagnostic potential of
miRNAs as biomarkers, the identification and characteriza-
tion of lncRNAs for HF could lead to realistic therapeutic
opportunities. However, before these opportunities can be-
come real, it is necessary that future studies define the
function of lncRNAs in driving the gene expression changes
underlying HF and their capacity to predict this pathology.
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